{"id":"zostavax-nonconcomitant","safety":{"commonSideEffects":[{"rate":"~25%","effect":"Injection site erythema"},{"rate":"~8%","effect":"Injection site swelling"},{"rate":"~48%","effect":"Injection site pain"},{"rate":"~1%","effect":"Headache"},{"rate":"~1%","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains a weakened live strain of varicella-zoster virus that replicates in the host, triggering both cellular and humoral immune responses. This immune activation provides protection against reactivation of latent VZV in individuals with prior chickenpox infection. The 'nonconcomitant' designation indicates the vaccine should not be administered simultaneously with certain other vaccines.","oneSentence":"ZOSTAVAX is a live attenuated vaccine that stimulates the immune system to prevent herpes zoster (shingles) by boosting varicella-zoster virus (VZV)-specific cell-mediated immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:30.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"}]},"trialDetails":[{"nctId":"NCT02519855","phase":"PHASE3","title":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-11","conditions":"Herpes Zoster","enrollment":882},{"nctId":"NCT00231816","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Herpes Zoster","enrollment":763}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ZOSTAVAX™ (Nonconcomitant)","genericName":"ZOSTAVAX™ (Nonconcomitant)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"ZOSTAVAX is a vaccine component that induces an immune response, used to prevent Herpes Zoster. It is administered nonconcurrently, meaning it is given separately from other vaccines.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}